0001209191-21-006328.txt : 20210129 0001209191-21-006328.hdr.sgml : 20210129 20210129201711 ACCESSION NUMBER: 0001209191-21-006328 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210127 FILED AS OF DATE: 20210129 DATE AS OF CHANGE: 20210129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Clayman Michael D. CENTRAL INDEX KEY: 0001597407 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36287 FILM NUMBER: 21573782 MAIL ADDRESS: STREET 1: C/O FLEXION THERAPEUTICS, INC. STREET 2: 10 MALL ROAD, SUITE 301 CITY: BURLINGTON STATE: MA ZIP: 01803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Flexion Therapeutics Inc CENTRAL INDEX KEY: 0001419600 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 MALL ROAD STREET 2: SUITE 301 CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: (781) 305-7777 MAIL ADDRESS: STREET 1: 10 MALL ROAD STREET 2: SUITE 301 CITY: BURLINGTON STATE: MA ZIP: 01803 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-27 0 0001419600 Flexion Therapeutics Inc FLXN 0001597407 Clayman Michael D. C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803 1 1 0 0 President and CEO Common Stock 2021-01-27 4 A 0 119500 0.00 A 275677 D Common Stock 2021-01-28 4 F 0 8776 12.37 D 266901 D Common Stock 347908 I By the Michael D.Clayman 2006 Revocable Trust Common Stock 24600 I By the Michael D. Clayman Irrevocable Trust Common Stock 388683 I By Versant Development Fund III, LLC On March 2, 2020, the Reporting Person was granted 175,000 restricted stock units. The vesting of the shares under the restricted stock unit award was to be based on the achievement of a specified amount of 2020 revenues from ZILRETTA product sales established at the time of the Compensation Committee's approval of the restricted stock unit award. On January 27, 2021, the Compensation Committee certified the achievement of a specified amount of 2020 revenues from ZILRETTA product sales resulting in the commencement of vesting of 119,500 shares. The remaining 55,500 restricted stock units granted to the Reporting Person on March 2, 2020, were forfeited based on the above performance metrics. The Reporting Person previously reported the restricted stock units in Table II of Form 4. Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on March 2, 2020. Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares. /s/ Mark S. Levine, Attorney-in-Fact 2021-01-29